Related Experiment Videos
Hematological side effects of co-trimoxazole
1Innere Medizin III, Zentrum für Innere Medizin, Ulm.
Infection
|January 1, 1987
Summary
Co-trimoxazole can decrease blood cells, with trimethoprim causing more frequent, dose-dependent side effects manageable with folate. Sulfamethoxazole rarely causes severe, unpredictable immune-mediated blood cell issues requiring drug cessation.
Area of Science:
- Pharmacology
- Hematology
- Immunology
Background:
- Co-trimoxazole is a commonly prescribed antibiotic.
- Hematological side effects are a known concern with antibiotic use.
- Understanding the specific risks of each component is crucial for patient safety.
Purpose of the Study:
- To differentiate and describe the hematological side effects of trimethoprim and sulfamethoxazole, the components of co-trimoxazole.
- To assess the frequency, severity, and management strategies for these side effects.
Main Methods:
- Review of clinical data and literature on co-trimoxazole-induced hematological adverse events.
- Analysis of side effect profiles attributed to trimethoprim versus sulfamethoxazole.
- Comparison of management and prevention strategies.
Main Results:
- Trimethoprim-related side effects are more common, dose-dependent, and typically manageable with folate supplementation.
- Sulfamethoxazole-related side effects are rare, idiosyncratic, immune-mediated, and potentially severe.
- Management for sulfamethoxazole-induced effects involves drug discontinuation and supportive care.
Conclusions:
- The hematological risks associated with co-trimoxazole differ significantly between its components.
- Trimethoprim's effects are generally predictable and preventable, while sulfamethoxazole's are rare but serious.
- Clinical vigilance and appropriate management are essential when prescribing co-trimoxazole, especially in at-risk populations.